title: Thioridazine inhibits risperidone metabolism: a clinically relevant drug interaction.
authors.forename: Taku
authors.initials: T
authors.lastname: Nakagami
authors.forename: Norio
authors.initials: N
authors.lastname: Yasui-Furukori
authors.forename: Manabu
authors.initials: M
authors.lastname: Saito
authors.forename: Kazuo
authors.initials: K
authors.lastname: Mihara
authors.forename: Ronald
authors.initials: R
authors.lastname: De Vries
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Kondo
authors.forename: Sunao
authors.initials: S
authors.lastname: Kaneko
mesh_terms: D000328:Adult; D000368:Aged; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000493:pharmacokinetics* / Q000627:therapeutic use; D001711:Biotransformation; D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics / Q000378:metabolism; D004347:Drug Interactions; D005260:Female; D005838:Genotype; D006801:Humans; D008297:Male; D008875:Middle Aged; D011569:Psychiatric Status Rating Scales; D018967:Risperidone / Q000493:pharmacokinetics* / Q000627:therapeutic use; D012559:Schizophrenia / Q000188:drug therapy / Q000235:genetics; D013881:Thioridazine / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D014150:Antipsychotic Agents; D019389:Cytochrome P-450 CYP2D6; D018967:Risperidone; D013881:Thioridazine